Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Maze Therapeutics, Inc.
No splits on record
Nothing in MAZE's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $0 | $167.5M | $0 | $0 |
| YoY Growth | - | - | - | - |
| Cost of Revenue | $2.4M | $0 | $0 | $0 |
| Gross Profit | -$2.4M | $167.5M | $0 | $0 |
| Gross Margin | - | 100.0% | - | - |
| Research and Development | $108.45M | $83.5M | $73.94M | $88.19M |
| Selling, General, and Administrative | $34.45M | $26.42M | $24.61M | $22.83M |
| Other | -$2.4M | $0 | $0 | $0 |
| Total Operating Expenses | $140.5M | $109.91M | $98.55M | $111.03M |
| Operating Income (EBIT) | -$142.9M | $57.59M | -$98.55M | -$111.03M |
| Operating Margin | - | 34.4% | - | - |
| Interest Expense | $0 | $0 | $0 | $0 |
| Interest Income | $11.78M | $4.65M | $1.97M | $2.03M |
| Other Income (Expense) | $11.78M | -$4.18M | -$1.86M | -$3.91M |
| Income Before Tax (EBT) | -$131.12M | $53.4M | -$100.42M | -$114.94M |
| Income Tax Expense | $0 | $1.17M | $0 | $0 |
| Net Income | -$131.12M | $52.23M | -$100.42M | -$114.94M |
| Net Income Margin | - | 31.2% | - | - |
| Supplementary Data | ||||
| EPS | -3.05 | 0.08 | -2.29 | -2.63 |
| Diluted EPS | -3.05 | 0.08 | -2.29 | -2.63 |
| Weighted Average OS | 42.98M | 43.80M | 43.78M | 43.78M |
| EBITDA | -$128.72M | $56.7M | -$96.33M | -$111.12M |
| EBITDA Margin | - | 33.9% | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $189.25M | $196.81M | $29.16M | $99.92M |
| Short-Term Investments | $152.67M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $341.92M | $196.81M | $29.16M | $99.92M |
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $7.8M | $4.86M | $4.95M | $6.23M |
| Total Current Assets | $349.72M | $201.67M | $34.11M | $106.15M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $25.16M | $29.92M | $34.98M | $41.23M |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $18.11M | $1.09M | $1.09M | $1.21M |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $4.14M | $7.87M | $1.32M | $1.37M |
| Total Long-Term Assets | $47.41M | $38.87M | $37.39M | $43.81M |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $397.13M | $240.54M | $71.5M | $149.96M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $1.79M | $1.94M | $2.02M | $1.58M |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $10.85M | $6.02M | $2.93M | $7.49M |
| Total Current Liabilities | $22.56M | $20.67M | $16.32M | $20.78M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $0 | $0 | $20.08M | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $1.09M | $969K | $1 | $0 |
| Total Long-Term Liabilities | $19.61M | $22.96M | $45.13M | $27.73M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $42.16M | $43.64M | $61.45M | $48.51M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $508.09M | $383.9M | $383.9M |
| Common Stock | $49K | $2K | $22K | $21K |
| Retained Earnings | -$489.55M | -$358.43M | -$395.69M | -$295.27M |
| Comprehensive Income & Other | $110K | $0 | $0 | $0 |
| Other Stockholders' Equity | $844.46M | $555.33M | $405.72M | $396.69M |
| Total Equity | $354.97M | $196.9M | $10.05M | $101.44M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $397.13M | $240.54M | $71.5M | $149.96M |
| Supplementary Data | ||||
| Total Debt | $23.31M | $26.63M | $49.62M | $32.05M |
| Net Debt | -$165.94M | -$170.18M | $20.46M | -$67.86M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$131.12M | $52.23M | -$100.42M | -$114.94M |
| Depreciation & Amortization | $2.4M | $3.3M | $4.09M | $3.82M |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $16.4M | $9.65M | $8.75M | $6.74M |
| Changes in Working Capital: | ||||
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | -$27K | -$204K | $399K | -$3.78M |
| Other Working Capital | -$2.25M | -$1.32M | -$6.71M | $541K |
| Total Working Capital Change | -$2.27M | -$1.52M | -$6.32M | -$3.24M |
| Other Non-Cash Items | $2.65M | $12.3M | $7.07M | $8.42M |
| Net Cash from Operating | -$111.94M | $75.95M | -$86.83M | -$99.2M |
| Investing Activities | ||||
| Capital Expenditures | -$794K | -$1.15M | -$441K | -$1.97M |
| Acquisitions | $0 | $0 | $0 | -$1.2M |
| Purchases of Investments | -$187.67M | $0 | $0 | $0 |
| Sales of Investments | $17.5M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$170.96M | -$1.15M | -$441K | -$3.17M |
| Financing Activities | ||||
| Debt Repaid | - | -$24.48M | -$16.18M | - |
| Common Stock Issuance | $275.84M | $68.37M | $209K | $1.73M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$500K | $0 | $0 | $0 |
| Net Cash from Financing | $275.34M | $92.85M | $16.39M | $1.73M |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$7.57M | $167.65M | -$70.88M | -$100.64M |
| Supplementary Data | ||||
| Operating Cash Flow | -$111.94M | $75.95M | -$86.83M | -$99.2M |
| Capital Expenditure | -$794K | -$1.15M | -$441K | -$1.97M |
| Free Cash Flow | -$112.73M | $74.81M | -$87.27M | -$101.17M |
| Cash at Beginning | $197.9M | $30.25M | $101.13M | $201.77M |
| Cash at End | $190.34M | $197.9M | $30.25M | $101.13M |